Our first drug candidate will be a topical formulation of cerium oxide nanoparticles for prevention of radiation dermatitis caused by radiotherapy. 


According to the American Cancer Society, carcinoma of the breast is the second leading cause of death in women in the United States with over 230,000 new cases and 40,000 deaths estimated in 2015. 

We plan to target patients who are receiving radiotherapy following breast-conserving surgery for early stage breast cancer. 


  • 170,000 Breast Cancer patients in the United States receive potentially life saving radiotherapy following breast-conserving surgery2
  • More than 95% of these patients are injured to some extent by the radiation therapy
  • More than 25% will develop skin damage severe enough to disrupt their radiation therapy3
  • No products have been approved for the prevention or mitigation of radiation dermatitis in this large group of patients
  • 100% of these patients are potentially treatable with a topical product


1American Cancer Society, Breast Cancer Facts and Figures, 2015-2016


2Kummerow KL, Dul, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015;150:9-16


3Pignol et al., J Clin Oncol 26:2085-2092, 2008 


Print Print | Sitemap
© Biocurity